Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies
if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the
same subfield and year (this is the minimum needed to enter the top 1%, not the average
within it), or reaches the top citation threshold in at least one of its specific research
topics.
Clinical Evaluation of a New Antimetabolite, 6-Mercaptopurine, in the Treatment of Leukemia and Allied Diseases
1953282 citationsJoseph H. Burchenal, M. Lois Murphy et al.Bloodprofile →
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late)
cites ·
hero ref
This map shows the geographic impact of C. P. Rhoads's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. P. Rhoads with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. P. Rhoads more than expected).
This network shows the impact of papers produced by C. P. Rhoads. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. P. Rhoads. The network helps show where C. P. Rhoads may publish in the future.
Co-authorship network of co-authors of C. P. Rhoads
This figure shows the co-authorship network connecting the top 25 collaborators of C. P. Rhoads.
A scholar is included among the top collaborators of C. P. Rhoads based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with C. P. Rhoads. C. P. Rhoads is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
Weinfeld, Herbert, et al.. (1957). The utilization of nucleotides by the mammal. VI. Purine nucleotides totally labeled with C14 in mice bearing sarcoma 180.. PubMed. 17(2). 122–6.1 indexed citations
Bennett, L. Lee, Howard E. Skipper, Christiane Stock, & C. P. Rhoads. (1955). Searches for exploitable biochemical differences between normal and cancer cells. II. Nucleic acid purine metabolism in human tumors.. PubMed. 15(3). 262–6.21 indexed citations
Burchenal, Joseph H., M. Lois Murphy, Rose Ruth Ellison, et al.. (1953). Clinical Evaluation of a New Antimetabolite, 6-Mercaptopurine, in the Treatment of Leukemia and Allied Diseases. Blood. 8(11). 965–999.282 indexed citations breakdown →
Lieberman, Seymour, et al.. (1952). STUDIES IN STEROID METABOLISM. Journal of Biological Chemistry. 196(2). 793–805.9 indexed citations
18.
Lieberman, Seymour, et al.. (1952). Studies in steroid metabolism. XIV. The isolation from human urine of delta9 17-ketosteroids.. Journal of Biological Chemistry. 196(2). 793–805.10 indexed citations
19.
Rhoads, C. P.. (1952). INTRODUCTION. Annals of the New York Academy of Sciences. 54(6). 872–873.3 indexed citations
20.
Stock, Christiane, Sonja M. Buckley, Kanematsu Sugiura, & C. P. Rhoads. (1951). A comparison of the retardation of Sarcoma 180 by SK 1424, 3-Bis (beta-chloroethyl) aminomethyl-4-methoxymethyl-5-hydroxy-6-methyl-pyridine with that by HN2, Methylbis (beta-chloroethyl) amine.. PubMed. 11(6). 432–6.8 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.